Novartis: ianalumab disease activity in Sjögren's disease kept improving to week 108 of monthly dosing
Ianalumab, an anti-B-cell antibody under regulatory review, showed further improvement in Sjögren's disease activity over two years of monthly dosing, according to Novartis.
Novartis reported that in patients with Sjögren's disease who received ianalumab monthly for two years, disease activity continued to improve through week 108, ad-hoc-news.de reports ad-hoc-news.de
ad-hoc-news.dead-hoc-news.deOpen source ↗. The company presented the results on Tuesday in a poster session at the annual congress of the American College of Rheumatology.
Sjögren's disease is an autoimmune disorder that mainly affects the glands and causes severe dryness of the eyes and mouth. It can also damage other organs.
Ianalumab is a monoclonal antibody that targets B cells, which play an important role in this autoimmune disease. The drug candidate is under regulatory review in several countries. In the US, a decision by the FDA is expected before the end of the current year.
